The Molbio Diagnostics IPO is one of the most awaited public issues in the Indian stock market. The company has built a strong name in the healthcare sector with its diagnostic products and testing solutions. It became well known for its Truenat testing platform, which many hospitals and laboratories use to detect different diseases.
The company now plans to raise money from the public through its Initial Public Offering (IPO). Investors who want to apply for this IPO should know the important dates, issue details, company background, and financial performance before they make any investment decision.
Molbio Diagnostics IPO Timeline
The subscription for the Molbio Diagnostics IPO will open on 10 August 2026. Investors can apply for the IPO until 12 August 2026.
The company expects to complete the allotment process on 13 August 2026. Refunds and credit of shares into demat accounts will take place on 14 August 2026. If everything goes as planned, the shares will list on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on 17 August 2026.
These dates help investors plan their application and keep track of the listing process.
Molbio Diagnostics IPO Price Band
At present, the company has not announced the official price band for the IPO. Investors must wait for the Red Herring Prospectus (RHP), which will confirm the final price band.
The RHP will also provide other important details such as the lot size, minimum investment amount, and other terms of the public issue. Until then, the price at which investors can apply remains unknown.
Issue Size and Structure
The Molbio Diagnostics IPO is a book-built issue.
The company plans to raise ₹200 crore through a fresh issue of equity shares. Along with the fresh issue, the IPO also includes an Offer for Sale (OFS) of up to 1.26 crore equity shares by existing shareholders.
The face value of each equity share is ₹1.
The fresh issue will bring new money into the company. The Offer for Sale allows some existing shareholders to sell part of their holdings through the IPO.
Share Allocation
The IPO follows the standard allocation pattern that many book-built public issues use.
About 50% of the issue has been reserved for Qualified Institutional Buyers (QIBs). Around 35% of the shares have been reserved for retail investors. The remaining 15% has been set aside for Non-Institutional Investors (NIIs) or High Net-worth Individuals (HNIs).
This allocation gives different categories of investors an opportunity to participate in the IPO.
About Molbio Diagnostics
Molbio Diagnostics is a healthcare technology company based in Goa. The company develops molecular diagnostic products that help doctors detect diseases quickly and accurately.
Its best-known product is the Truenat platform. This portable testing system can detect diseases such as tuberculosis (TB), COVID-19, HIV, hepatitis, and several other infectious diseases.
The portable nature of the Truenat platform makes it useful even in places where large laboratory facilities are not available. This has helped the company build a strong presence in India and many international markets.
Today, Molbio Diagnostics exports its products to several countries. The company continues to expand its reach with advanced diagnostic solutions that support healthcare providers across different regions.
Financial Performance
The company’s financial performance shows steady growth.
For FY2026, Molbio Diagnostics reported revenue of ₹1,455.17 crore. During the same financial year, the company posted a net profit of ₹164.14 crore.
Both revenue and profit increased compared with the previous financial year. Better financial performance often reflects business growth, although investors should study all available information before making any investment decision.
The final Red Herring Prospectus will provide additional financial details and risk factors for investors.
Why Investors Are Watching This IPO
Many investors have shown interest in the Molbio Diagnostics IPO because the company operates in the healthcare and diagnostics sector. Healthcare remains an important industry, and diagnostic testing plays a major role in disease detection and patient care.
The company has already built a strong reputation through its Truenat platform. Its presence in both Indian and international markets has also attracted attention.
At the same time, every IPO carries risks. Market conditions, company performance, industry competition, and valuation all influence future returns. Investors should carefully read the official documents before they decide to apply.
What Investors Should Watch Before Applying
The most important information is still awaited. The company has not yet announced the official price band. The lot size and minimum investment amount also remain unavailable.
These details will become public once the company releases the Red Herring Prospectus. Investors should review the prospectus carefully because it contains information about the company’s business, financial results, risks, objectives of the issue, and valuation.
Checking these details can help investors make a more informed decision.
Final Thoughts
The Molbio Diagnostics IPO has already attracted attention because of the company’s strong position in the molecular diagnostics market. The issue will open on 10 August 2026 and close on 12 August 2026, with the expected stock market listing on 17 August 2026.
The IPO includes a ₹200 crore fresh issue along with an Offer for Sale of up to 1.26 crore equity shares. The company has not yet announced the official price band, so investors must wait for the Red Herring Prospectus for complete information.
Molbio Diagnostics has built a solid reputation with its Truenat testing platform and has reported FY2026 revenue of ₹1,455.17 crore and net profit of ₹164.14 crore. These numbers show business growth, but every investment decision should come after careful research and a close look at the company’s official IPO documents.
FAQs
1. When will the Molbio Diagnostics IPO open?
The Molbio Diagnostics IPO will open for subscription on 10 August 2026 and will close on 12 August 2026.
2. What is the price band of the Molbio Diagnostics IPO?
The company has not announced the official price band yet. It will be available after the release of the Red Herring Prospectus (RHP).
3. What is the issue size of the Molbio Diagnostics IPO?
The IPO includes a fresh issue of ₹200 crore and an Offer for Sale (OFS) of up to 1.26 crore equity shares.
4. What does Molbio Diagnostics do?
Molbio Diagnostics is a Goa-based healthcare company that develops molecular diagnostic solutions. Its Truenat platform helps detect diseases such as tuberculosis (TB), COVID-19, HIV, hepatitis, and other infectious diseases.
5. When are the shares of Molbio Diagnostics expected to list?
The shares of Molbio Diagnostics are expected to list on the BSE and NSE on 17 August 2026, subject to the completion of the IPO process.
ALSO READ: Oman Suggests a New Shipping Plan for the Strait of Hormuz
